Supercharged immune cells take aim at cancer and viruses in one shot
NCT ID NCT00840853
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study tests a new type of immune cell therapy for people with CD19-positive leukemia or lymphoma who have had a stem cell transplant. The cells are specially designed to both recognize and kill cancer cells (through a CD19-targeting antibody) and fight three common viruses (CMV, EBV, and adenovirus). The goal is to see if these cells can safely prevent relapse and infections, and how long they last in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gene-modified T cells that target CD19 and three common viruses (CMV, EBV, adenovirus)
- What this could lead to
- If successful, this approach could provide a long-lasting, dual-action therapy that prevents both viral infections and cancer relapse after stem cell transplant, potentially curing patients who would otherwise have few options.
- What could go wrong
- This is an early-phase trial focused on safety and dosing, so the treatment may not work as hoped. There is a risk of serious side effects, including graft-versus-host disease (GVHD) and other toxicities.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can targeted drugs blinatumomab and venetoclax improve outcomes for childhood leukemia?
- Targeted drug aims to clear hidden leukemia before transplant
- Double-Pronged immune cells take aim at stubborn blood cancers
- Engineered t cells with a kill switch aim to make stem cell transplants safer
- Engineered immune cells take aim at Tough-to-Treat blood cancers
- Combination therapy aims to keep leukemia in check after transplant